These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24357810)

  • 1. Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.
    Guo X; Higgs BW; Rebelatto M; Zhu W; Greth W; Yao Y; Roskos LK; White WI
    Rheumatology (Oxford); 2014 Apr; 53(4):686-95. PubMed ID: 24357810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
    Higgs BW; Zhu W; Morehouse C; White WI; Brohawn P; Guo X; Rebelatto M; Le C; Amato A; Fiorentino D; Greenberg SA; Drappa J; Richman L; Greth W; Jallal B; Yao Y
    Ann Rheum Dis; 2014 Jan; 73(1):256-62. PubMed ID: 23434567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
    Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
    Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production.
    Sugiura T; Kawaguchi Y; Harigai M; Takagi K; Ohta S; Fukasawa C; Hara M; Kamatani N
    J Immunol; 2000 Jun; 164(12):6593-600. PubMed ID: 10843719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
    Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
    J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies.
    Notarnicola A; Lapadula G; Natuzzi D; Lundberg IE; Iannone F
    Scand J Rheumatol; 2015 May; 44(3):224-8. PubMed ID: 25379698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis.
    Pandya JM; Loell I; Hossain MS; Zong M; Alexanderson H; Raghavan S; Lundberg IE; Malmström V
    Arthritis Res Ther; 2016 Apr; 18():80. PubMed ID: 27039301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatomyositis and polymyositis: new treatment targets on the horizon.
    Hak AE; de Paepe B; de Bleecker JL; Tak PP; de Visser M
    Neth J Med; 2011 Oct; 69(10):410-21. PubMed ID: 22058260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.
    Loell I; Raouf J; Chen YW; Shi R; Nennesmo I; Alexanderson H; Dastmalchi M; Nagaraju K; Korotkova M; Lundberg IE
    Arthritis Res Ther; 2016 Jun; 18(1):136. PubMed ID: 27287443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations.
    Hengstman GJ; van den Hoogen FH; Barrera P; Netea MG; Pieterse A; van de Putte LB; van Engelen BG
    Eur Neurol; 2003; 50(1):10-5. PubMed ID: 12824706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.
    Sugihara T; Okiyama N; Watanabe N; Miyasaka N; Kohsaka H
    Arthritis Rheum; 2012 Aug; 64(8):2655-62. PubMed ID: 22392010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-lymphocyte immunophenotyping in polymyositis and dermatomyositis.
    Iannone F; Cauli A; Yanni G; Kingsley GH; Isenberg DA; Corrigall V; Panayi GS
    Br J Rheumatol; 1996 Sep; 35(9):839-45. PubMed ID: 8810666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis.
    Cherin P; Herson S; Crevon MC; Hauw JJ; Cervera P; Galanaud P; Emilie D
    J Rheumatol; 1996 Jul; 23(7):1135-42. PubMed ID: 8823683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis.
    Feng M; Guo H; Zhang C; Wang Y; Liang Z; Zhao X; Qin Y; Wu Y; Liu G; Gao C; Luo J
    Int Immunopharmacol; 2019 Dec; 77():105912. PubMed ID: 31669890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of autophagy in T‑cell survival in polymyositis and dermatomyositis.
    Shu X; Chen F; Peng Q; Lu X; Tian X; Wang Y; Wang G
    Mol Med Rep; 2017 Aug; 16(2):1180-1188. PubMed ID: 28586060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.
    Gabay C; Gay-Croisier F; Roux-Lombard P; Meyer O; Maineti C; Guerne PA; Vischer T; Dayer JM
    Arthritis Rheum; 1994 Dec; 37(12):1744-51. PubMed ID: 7986220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis.
    Sugiura T; Harigai M; Kawaguchi Y; Takagi K; Fukasawa C; Ohsako-Higami S; Ohta S; Tanaka M; Hara M; Kamatani N
    Int Immunol; 2002 Aug; 14(8):917-24. PubMed ID: 12147628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.